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ABSTRACT
Purpose Design and synthesis of a tumor responsive nanoparticle-
based system for imaging and treatment of various cancers.
Methods Manganese oxide nanoparticles (Mn3O4 NPs) were syn-
thesized and modified with LHRH targeting peptide or anti-
melanoma antibodies (cancer targeting moieties) and a MMP2 cleav-
able peptide (a possible chemotactic factor). Nanostructured lipid
carriers (NLCs) were used to entrap the BRAF inhibitor,
vemurafenib, and enhance cytotoxicity of the drug. Size distribution,
stability, drug entrapment, cytotoxicity and genotoxicity of synthesized
nanoparticles were studied in vitro. Enhancement of MRI signal by
nanoparticles and their body distribution were examined in vivo on
mouse models of melanoma, ovarian and lung cancers.
Results Uniform, stable cancer-targeted nanoparticles
(PEGylated water-soluble Mn3O4 NPs and NLCs) were synthe-
sized. No signs of cyto-,genotoxicity and DNA damage were
detected for nanoparticles that do not contain an anticancer drug.
Entrapment of vemurafenib into nanoparticles significantly en-
hanced drug toxicity in cancer cells with targeted V600E mutation.
The developed nanoparticles containing LHRH and MMP2 pep-
tides showed preferential accumulation in primary and metastatic
tumors increasing the MRI signal in mice with melanoma, lung and
ovarian cancers.
Conclusions The proposed nanoparticle-based systems provide
the foundation for building an integrated MRI diagnostic and
therapeutic approach for various types of cancer.
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Theragnostics is an emerging field in medical research that
can potentially improve overall patient therapy and outcome
by combining diagnostic and specific therapeutic properties
(1). Numerous research groups use various nanotechnology
approaches for developing theragnostic agents. Although
nanoparticles allow for distinct advantages in the field of
therapy of different diseases, a combination of both diagnostic
and therapeutic modalities in a single nanoparticle may be
associated with certain difficulties. While nanoparticle prop-
erties can be fine-tuned in regards to the size, surface groups,
and surface charge, synthesis of such a particle will be chal-
lenging due to the sheer number of modification steps in-
volved. In addition, a single particle with both diagnostic
and therapeutic capabilities may result in unnecessary
treatment of false-positive tissues. Therefore, it may be ideal
to develop a separated, but integrated multi-particle system
for theragnostics.
Medical imaging procedures such as computed tomogra-
phy (CT), X-ray, positron emission tomography (PET) and
magnetic resonance imaging (MRI) are very commonly uti-
lized in the clinic for the diagnosis and prognosis of various
diseases. Designing nanoparticle contrast agents for these
imaging modalities is an attractive and important goal. Each
imaging modality has its strengths and limitations and the use
of several type of imaging agents in combination may gain
additional benefits in terms of revealing hidden details and
improving the reliability of a diagnosis. MR imaging often
represents the preferred modality for its cost efficacy and the
non-invasive and non-ionizing nature (2). In addition, MRI
provides anatomical images at high resolutions (3) thus mak-
ing it an attractive imaging approach for the detection of small
tumors and metastases.
Resolution of target structure or tissue can be enhanced by
the use of MRI contrast agents, which are sub-divided into
either T1-positive (paramagnetic) or T2-negative
(superparamagnetic) agents (4). Gadolinium chelates have
been FDA approved for use as contrast agents for MRI.
However, possible induction of nephrogenic systemic fibrosis
is a concern with these agents. In addition, the small size of the
chelate imaging agents results in short circulation times (5).
This may result in insufficient concentrations accumulated at
spots of interests. It was concluded that a circulation half-life of
2 to 6 h would allow for adequate accumulation at target sites
and therefore increased contrast (6). Nanoparticles have been
extensively investigated for the delivery of small molecules and
nucleic acids and as well as for imaging purposes (7). In
addition, many types of nanoparticles have been investigated
as optical imaging probes. Although optical imaging works
well for small animals, its utilization for larger animals and
humans represent certain difficulties. In addition, optical
approach is not ideal for imaging of deeper anatomical
structures (8). Moreover, instruments for optical imaging have
yet to be fully developed for humans. Consequently, MRI
especially in combination with nanoparticle-based contrast
agents represents themost valuable approach for the detection
of primary tumors and metastases.
It is known that nanoparticles coated with polyethylene
glycol (PEG) polymer chains (PEGylated) may achieve circu-
lation times up to several days (6). With the customizable
nature of properties of such nanoparticles, nanocarriers for
contrast enhancing agents with an optimal circulation time
can be designed for imaging. In addition, the surface of such
long-circulating nanocarriers can be modified with targeting
ligands to improve targeting of imaging moieties specifically to
cells and tissues of interest, e.g. primary localized and spread-
ing tumors as well as metastases. Previously we have shown
that many types of cancer cells overexpress luteinizing
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hormone releasing hormone (LHRH) receptors and LHRH
peptide was successfully used in our laboratory as a targeting
moiety for delivering drugs to tumors (9–17). Most imaging
nanoparticles contain metal oxides and the cores of these
particles are frequently synthesized at high temperatures and
in inert atmospheres (18). Superparamagnetic iron oxide
nanoparticles (SPIONs) are often employed as T2-negative
contrast agents. However, the utilization of SPIONs as MRI
contrast enhancers is hindered due to their negative contrast
effect and tendency to include artifacts in the images (19).
Recently, manganese oxide nanoparticles have begun to be
investigated as positive MRI contrast agents (2,19–23).
However, manganese-based contrast agents are not as well-
studied as SPIONs.
Nanoparticle-based contrast agents are endowed with their
imaging capabilities primarily due to the properties of their
cores. Since the nanocrystal cores of such nanoparticles are
not water soluble, a coating layer is required in order to
provide for intravascular injection or oral delivery and trans-
port of the nanoparticles in the systemic circulation. The most
common coatings for manganese-based contrast agents are
silica shells (3,4) and lipid-PEG molecules (22,24). In the form
of coated nanoparticles, manganese atoms have a little contact
with water and therefore bulk arrangement of atoms as in
nanoparticles have low molar relaxivities and result in low
positive contrast (20). When Mn2+ ions are released from the
bulk nanocrystal structure inside cells after endocytosis (mainly
under the action of low pH in endosomes), the ability of
magnesium compounds to increase the relaxation rates of
the surrounding water proton spins and therefore molar rela-
tivity may increase 10-fold.
Once the disease is diagnosed, it is important to deliver
therapeutic agents to treat or cure the disease. Cytotoxic drugs
are widely used for therapy of many types of cancers. Despite
improvements in drug design and chemotherapy combina-
tions, several challenges still limit the efficiency of the treat-
ment. Conventional small molecule chemotherapeutic drugs
lack specificity, possess high toxicity, and frequently induce
drug resistance. Improvements in genetic analysis of cancers
and computation have led to design of more selective and
more potent drugs. Yet, the challenges faced by conventional
chemotherapeutics have not been completely overcome, by
only mitigated in part.
Nanoparticle-based delivery of chemotherapeutics has be-
come a widely spreading area of research. Polymers,
dendrimers, liposomes, emulsions, and inorganic nanoparti-
cles have been extensively studied for the delivery of small
molecules (13,14,25–31). More recently, solid lipid nanopar-
ticles (SLNs) and nanostructured lipid carriers (NLCs) have
begun to be increasingly investigated to overcome problems
associated with other nanoparticle carriers (15,32–34). The
most of novel and potent chemotherapeutic drugs tend to
have very poor water solubility; therefore, entrapment in a
lipid-based carrier may substantially improve their bioavail-
ability and enhance the treatment efficacy. Although emul-
sions and liposomes are typically synthesized with well-studied
excipients and can be produced on large scales, they have a
limited ability to protect and modulate release of loaded drugs
(35). Whereas SLNs are colloids consisting of solid lipids,
NLCs contain liquid lipid entrapped within the voids of a
spatially different solid lipid matrix (36). The liquid lipid
appears not to affect the crystal structure of the solid lipid
(37). Lipophilic drugs are solubilized in the liquid lipid and
thus entrapped within the solid lipid matrix. Therefore, the
loading capacity and effective drug release of NLCs is better
when compared with SLNs (34,37).
In the present study, we have designed and tested biocom-
patible manganese oxide nanocrystals, which are capable of
enhancing diagnosis and imaging of melanoma, ovarian and
lung cancers using monoclonal antibodies or peptide cancer
targeting moieties. We also demonstrated the ability to specif-
ically target primary and metastatic tumors and diagnose
them with efficient positive contrast ability. In addition, a
cleavable peptide was conjugated onto the surface of the
developed nanoparticles to act as a potential chemotactic
messenger. Once deposited at tumor sites, matrix metallopro-
teinases can cleave a fragment off of the attached peptide. The
detached peptide can diffuse away from the tumor site and
into the systemic circulation. A concentration gradient of
cleaved peptide fragments can be established, higher in prox-
imity to the tumor site and lower farther away from tumor.
Therapeutic nanoparticles modified with avidin can bind to
and potentially be recruited to the tumor site. This presents a
novel paradigm in targeted delivery whereby the target is not
a cell-surface receptor on cancer cells, but rather a messenger
molecule. A chemotherapeutic agent, vemurafenib, was fur-
thermore entrapped in NLCs in order to effectively reach sites
of melanoma tumors and metastases.
MATERIALS AND METHODS
Materials
Manganese (II) chloride, oleic acid, N-hydroxysuccimide
(NHS), 3,3′,5,5′-tetramethylbenzidine (TMB), oleylamine,
phosphoric acid (>85% wt.), calcium chloride, ethylenedi-
aminetetraacetic acid (anhydrous, Sigma grade, approx.
99% t i t r a t i on , EDTA) , 4 - ( 2 - hyd roxye thy l ) - 1 -
piperazineethanesulfonic acid (HEPES), sodium chloride, hy-
drochloric acid (molecular biology grade, 36.5–38.0%), hy-
droxylamine hydrochloride (ReagentPlus®, 99%), Tween®
80, and S-acetylthioglycolic acid N-hydroxysuccinimide ester
(SATA, ≥ 95%TLC) were purchased from Sigma-Aldrich (St.
Louis, MO). Chloroform (HPLC grade), dimethyl sulfoxide
(DMSO), reagent alcohol, xylenes, sodium dodecyl sulfate
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(SDS), N,N-dimethylformamide (DMF), sodium hydroxide
(10 N solution, 30% w/w), 1× phosphate buffered saline (PBS)
were purchased from Fisher Scientific (Fair Lawn, NJ). Pierce®
Avidin, 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydro-
chloride (EDC) were purchased from Thermo Scientific
(Rockford, IL). SYBR® Gold nucleic acid gel stain was pur-
chased from Life Technologies (Carlsbad, CA). Isopropyl
myristate (96%) and 1-octadecene were purchased from Acros
Organics. Cy5.5 Mono NHS-Ester was supplied from GE
Healthcare Life Sciences (Piscataway, NJ). 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[Maleimide(Polyethylene
Glycol) 2000] ammonium salt (DSPE-PEG-MAL), 1,2-
d i s t e a roy l - s n - g l y c e ro -3 -pho sphoe thano l am ine -
N-[Amino(Polyethylene Glycol) 2000] ammonium salt (DSPE-
PEG-NH2), soy L-α-phosphatidylcholine (soy PC), and 1,2-
dioleolyl-3-trimethylammonium-propane chloride salt
(DOTAP) were purchased from Avanti Polar Lipids
(Alabaster, AL). Anti-Melanoma antibody ab733was purchased
from Abcam (Cambridge, MA). Precirol® ATO 5 was a kind
gift fromGattefosse (Paramus, NJ). Vemurafenib was purchased
from Selleckchem (Houston, TX). Custom luteinizing hormone
releasing hormone (LHRH) and cleavable by matrix metallo-
proteinase 2 (MMP2) peptides were manufactured by American
Peptide Company (Sunnyvale, CA) according to our design.
The LHRH targeting peptide had the amino acid sequence of
Gln-His-Trp-Ser-Tyr-D-Lys(D-Cys)-Leu-Arg-Pro-NHEt. A
custom MMP2 peptide contained the sequence of Biotin-Gly-
Pro-Leu-Gly-Ile-Ala-Gly-Gln. Human active, recombinant
MMP2 enzyme (MW 66 kDa) was purchased from EMD
Millipore (Darmstadt, Germany).
Synthesis of Mn3O4 Hydrophobic Cores
Manganese oxide (Mn3O4) hydrophobic cores were synthe-
sized according to the published protocol (24). Briefly, one
mmol of manganese (II) chloride, two mmol of oleic acid, and
ten mmol of oleylamine were dissolved in 15 mL of xylenes at
atmospheric conditions. The solution was heated and once it
reached 90ºC, 3 mL of deionized water was added. The
reaction was allowed to age at 90ºC for 3 h. The hydrophobic
cores were precipitated with the addition of reagent alcohol
and isolated by centrifugation. The dry cores were waxy and
weighed before being dispersed in chloroform.
Synthesis of Water Soluble Mn3O4 Nanoparticles
(NH2/MAL Mn3O4 NPs)
Hydrophobic Mn3O4 cores (10 mg), 20 mg of DSPE-PEG-
NH2 and 5 mg of DSPE-PEG-MAL were mixed in 2 mL
chloroform. After proper mixing, the reaction mixture was
heated to 60ºC and 8 mL of DMSO was slowly added. The
reaction was stopped after all of the chloroform had evapo-
rated. The used solvent exchange method is more appropriate
when compared with other coating methods such as thin film
hydration because the resulting hydrophilic particles are more
uniform and stable.
Conjugation of MMP2 Cleavable Peptide (MMP2/MAL
Mn3O4 NPs)
A custom peptide (biotin-Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln)
that is cleaved specifically by MMP2 enzyme (38) was at-
tached to NH2/MAL Mn3O4 NPs using amide bond. The
carboxy terminal of the MMP2 cleavable peptide would react
with the surface free amines on the NH2/MAL Mn3O4 NPs.
The free carboxyl on the MMP2 cleavable peptide was acti-
vated using EDC and NHS cross linkers. After 15 min, NH2/
MAL Mn3O4 NPs were added. The reaction was allowed to
continue for 24 h. The resultant conjugate was dialyzed
against deionized water.
For in vivo biodistribution studies and peptide cleavage
study, the MMP2 cleavable peptide without biotin (Gly-Pro-
Leu-Gly-Ile-Ala-Gly-Gln) was reacted with Cy5.5-NHS ester.
After 24 h of allowing for conjugation, the resulting Cy5.5-
MMP2 was conjugated onto NH2/MAL Mn3O4 NPs as
described above to yield Cy5.5-MMP2/MAL Mn3O4 NPs.
Attachment of LHRH Targeting Moiety (MMP2/LHRH
Mn3O4 NPs)
Previous studies have shown the ability of LHRH peptide
(Gln-His-Trp-Ser-Tyr-DLys(DCys)-Leu-Arg-Pro-NHEt) to
target various delivery systems specifically to different cancer
cells (10–12). After attaching the MMP2 cleavable peptide, a
thioether linkage was synthesized using the maleimide moiety
on the MMP2/MAL Mn3O4 NP and the cysteine residue on
LHRH peptide. In 100 mM phosphate buffer, 10 mg of
custom LHRH peptide was reacted with previously synthe-
sized MMP2/MAL Mn3O4 NPs. The reaction was per-
formed at 4ºC overnight. The resultant conjugate was dia-
lyzed against deionized water. The presence and amount of
attached peptide was confirmed and measured using the
Pierce® Bicinchoninic Acid (BCA) Protein Assay Kit
(Thermo Scientific, Rockford, IL).
Attachment of Anti-MelanomaAntibody (MMP2/ab733
Mn3O4 NPs)
The antibody modification and attachment protocol was
adapted from Na et al. (22). An anti-melanoma antibody
cocktail was purchased from Abcam (Cambridge, MA). The
mixture is able to target neuraminidase-sensitive side chain in
immature melanosomes (HMB45 antibody), melanoma anti-
gen recognized by T cells (MART-1, DT101 and BC199
antibodies), and tyrosinase (T311 antibody). Briefly, ab733
Anti-Melanoma antibodies in 0.5 mL PBS was reacted with
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60 μL of SATA in DMSO (1.5 mg/mL) for 30 min.
Afterwards, 120 μL hydroxylamine (0.5 M in PBS) was added
and the reaction was allowed for 2 h at room temperature.
The modified antibody was purified using Amicon® centrif-
ugal device (MWCO 30 kDa, Millipore, Billerica, MA). The
purified product was added to MMP2/MALMn3O4 NPs in
100 mM phosphate buffer. The reaction was performed at
4ºC overnight. The resultant conjugate was dialyzed against
deionized water.
Quantification of Manganese Content in Mn3O4 NP
Formulations
Manganese concentration in the NP formulation was assessed
using a colorimetric assay. The original assay, developed for
photosynthetic membranes (39), was adapted for assessing the
manganese content of NPs. Briefly, conjugates were digested
using concentrated hydrochloric acid. After the particles were
disintegrated, the solution was diluted with deionized water
and concentrated sodium hydroxide solution was added to
create a basic pH solution. 3,3′,5,5′-tetramethylbenzidine
(TMB) dissolved in 0.1 M hydrochloric acid was added and
a precipitate was formed. Addition of 5.3 M phosphoric acid
dissolved the crystals. The absorbance of the solution was
measured at 450 nm wavelength. The manganese concentra-
tion was calculated based on a calibration curve.
MMP2 Gene Expression
RNAwas isolated from ovarian cancer cell lines using RNeasy
kit (Qiagen, Frederick, MA) following the manufacturer’s
protocol. Ready-To-Go You-Prime First Strand Beads
(Amersham Biosciences, Piscataway, NJ) was mixed with
1 μ g o f t o t a l RNA a nd 1 0 0 n g o f r a n d om
hexadeoxynucleotide primer (Amersham Biosciences,
Piscataway, NJ) to synthesize cDNA. The reaction mixture
was subjected to quantitative polymerase chain reaction
(qPCR) using SYBR® Green Master Mix as a detection
agent. Qiagen (Frederick, MA) software was used to calculate
difference in MMP2 gene expression between the cell lines by
first normalizing the MMP2 gene expression in each cell line
with that of β-actin, a housekeeping gene.
Digestion of MMP2-Cleavable Peptide
The protocol was adapted from a previous study (38). A small
amount of Cy5.5-MMP2/LHRHMn3O4 NPs and 1 mg/mL
of human MMP2 enzyme was mixed in HEPES buffered
saline. At selected time intervals, a small amount was removed
and centrifuged using Amicon® centrifugal device (MWCO
30 kDa, Millipore, Billerica, MA). The retentate was re-
dissolved in buffer and the fluorescence signal was measured
for Cy5.5 (λex=670 nm, λem=690 nm). Cy5.5 dye was
conjugated to the terminal end of the MMP2 cleavable pep-
tide. Therefore, when the peptide is cleaved between glycine
and isoleucine, the portion of Cy5.5-Gly-Pro-Leu-Gly is no
longer attached to the surface of the nanoparticles and thus
can be removed by centrifugal filtration.
Synthesis of Nanostructured Lipid Carriers (NLCs)
A previously published protocol from our group was adapted
for this project (15). Briefly, a melted ultrasonic dispersion
method was utilized to synthesize vemurafenib (Vem) contain-
ing NLCs. Vemurafenib dissolved in DMSOwas mixed into a
hot lipid phase, which consisted of 100 Precirol ATO 5
(Gattefossé USA, Paramus, NJ), 100 mg isopropyl myristate,
and 5 mg soy PC. The aqueous phase was composed of
250 mg Tween® 80, 10 mg DSPE-PEG-NH2, and 25 mg
DOTAP in 10 mL deionized water. Both phases were heated
to 80ºC in a silicone oil bath. After 15 min, the lipid phase was
added to the aqueous phase while homogenizing at
12,000 rpm for 5 min using a high-speed homogenizer
(PRO Scientific Inc., Oxford, CT). The emulsion was subject
to ultrasonication (Model 120 Sonic Dismembrator, Fisher
Scientific, Fairlawn, NJ) for 5 min at 3 W. The resulting
emulsion was cooled to 4ºC in ice while being magnetically
stirred. The NLC emulsion was dialyzed against deionized
water using a membrane (MWCO 15 kDa) at 4ºC overnight.
The dialyzed emulsion was stored at 4ºC. Empty NLCs were
prepared in the same manner with equal volume of DMSO
instead of vemurafenib.
Vemurafenib HPLC Calibration Curve
Previously, a published protocol was modified for measuring
vemurafenib concentration by HPLC (40). The chromatog-
raphy system consisted of aWaters 1,525 with a Binary pump,
Waters 2,487 Dual wavelength absorbance detector, Waters
717 plus autosampler, and Breeze workstation (Waters Corp,
Milford, USA). The stationary phase consisted of a C8
Xterra® MS (250 mm×4.6 mm, 5 μm; Waters Corp,
Milford, USA) column with a guard column and a mixture
of 100 mM glycine buffer (pH 9.00) and acetonitrile (45:55,
v/v) was used for the mobile phase. Each sample was subjected
to a 15min run at a flow rate of 0.9 mL/min at 30ºC. The UV
detector was used to detect vemurafenib at a wavelength of
249 nm.
Vemurafenib Entrapment Efficiency and Loading
in NLCs
Due to the high hydrophobicity of vemurafenib, the concen-
tration of free dissolved in the water phase drug is negligible.
In order to measure the concentration of bound drug, the
NLC-vemurafenib conjugates were disrupted by mixing with
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4× volume of methanol. Then, the mixture was sonicated for
10 min and centrifuged at 3,500 rpm for 15 min. The super-
natant was collected and analyzed using described above
HPLC protocol.
NLC Drug Entrapment Stability
The entrapment stability of vemurafenib in NLC formulation
was studied using dialysis. A small volume of Vem-NLC
dispersion was loaded in a dialysis membrane (Spectra/
Por® Biotech RC dialysis membrane, MWCO 15 kDa,
Spectrum Laboratories Inc., Houston, TX) and placed in
phosphate buffered saline containing 15% ethanol and stirred
with a magnetic stirrer at 37ºC. At pre-determined time
intervals, a small amount of Vem-NLC dispersion was re-
moved from the membrane as well as the medium. The
Vem-NLC sample was disrupted as above and both samples
(Vem-NLC and medium) were run on HPLC to assess
vemurafenib concentration.
Size Distribution, Cytotoxicity and DNA Damage
The size distributions of MMP2/LHRH Mn3O4 NPs and
Vem-NLC formulations were measured using Malvern
ZetaSizer NanoSeries (Malvern Instruments, Malvern, UK)
according to the manufacturer’s recommendations.
Measurements were performed at 25ºC. The sizes were mea-
sured five times, and average values were calculated. The
cytotoxicity of MMP2/LHRH Mn3O4 NPs and empty
NLCs were assessed using a modified MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as previ-
ously described (41). Briefly, CHO-K1 cells (a model for
normal cells) were plated in a 96 well plate at a density of
10,000 cells/well. Twenty-four hours after seeding, different
concentrations MMP2/LHRH Mn3O4 NP conjugates were
added to the cells. Control cells were treated with an equal
volume of fresh medium. The cells were treated for 24 h. The
liquid was removed and replaced with fresh medium and
MTT solution. After further 3 h incubation, a solubilizing
solution was added and the plates were stored overnight. The
absorbance intensity was measured the following day. The
cytotoxicity of drug-containing formulations was measured
using metastatic melanoma cell line, Colo 829, which
expressed the V600E mutation. The following formulations
were assessed: free non-conjugated vemurafenib (Vem) and
vemurafenib entrapped in NLCs (Vem-NLC).
The CometAssay® HT kit (Trevigen, Gaithersburg, MD)
was used as a sensitive genotoxicity test for the detection of
DNA damage induced by MMP2/LHRH Mn3O4 NPs and
NLCs. Approximately 300,000 CHO-K1 cells were plated in
a 25 cm2 cell culture flasks and incubated for 24 h prior to
treatment. Cell culture medium was replaced with either fresh
medium (negative control), medium containing 100 μM of
hydrogen peroxide (positive control), non-cytotoxic concen-
tration of MMP2/LHRH Mn3O4 NP (7.1 mg/l Mn
2+) or
empty NLCs (80 mg/l lipid concentration) for 24 h. After the
treatment, the cells were pelleted and suspended in ice-cold
PBS buffer at a concentration of 1×105 cells/ml. The cell
suspension was mixed with molten COMET Agarose at a
ratio of 1:10 (v/v). A small aliquot was pipetted onto the
surface of a COMET slide. After solidification, the slides were
immersed in lysis solution at 4ºC for 30 min and then in
alkaline unwinding solution for 60 min at room temperature.
The slides were placed in a horizontal electrophoresis appa-
ratus containing enough 1× TBE buffer to cover the samples.
Minimal voltage was applied for 45min. Afterwards, the slides
were rinsed with deionized water and 70% ethanol. Samples
were air dried to bring all cells into a single plane. DNA was
stained with SYBR Gold (Life Technologies, Carlsbad, CA)
for 30 min. The samples were rinsed with deionized water,
dried, and viewed using a fluorescence microscope. DNA
damage was assessed by calculating the percent of DNA in
the comet tail using CometScore™ (TriTek Corp.,
Sumerduck, VA) software.
Cancer Cells
Human lung (A549), ovarian (A2780), melanoma (COLO
829) cancer cells and Chinese hamster ovary cells (CHO-
K1) were purchased from ATCC (Manassas, VA). A549 cells
expressing luciferase enzyme were purchased from Xenogen
Bioscience (Cranbury, NJ). The ascitic fluid with cancer cells
was obtained from the peritoneum area of the patients with
ovarian cancer provided by the Cancer Institute of New
Jersey. The samples were centrifuged for 20 min at 2,000 g;
the supernatant was discarded and cell pellets were conse-
quently re-suspended. The re-suspended cells were cultured in
RPMI 1,640 media with L-glutamine (Lonza, Walkersvile,
MD) supplemented with 15% fetal bovine serum
(Invitrogen, Carlsbad, CA), 2.5 μg/ml insulin (Sigma, St.
Louis, MO) and 1.2 mL/100 mL penicillin-streptomycin
(Gibco, Grand Island, NY). A549, A2780, and COLO 829
cells were grown in RPMI 1,640 medium (Lonza,
Walkersville, MD) supplemented with 10% fetal bovine serum
(Life Technologies, Carlsbad, CA) and 1.2 mL/100 mL
penicillin-streptomycin (Life Technologies, Carlsbad, CA).
CHO-K1 cells were grown in F12-K medium supplemented
with 10% fetal bovine serum (Life Technologies, Carlsbad,
CA). All cells were grown in a humidified atmosphere of 5%
CO2 (v/v) at 37°C. All experiments were performed on the
cells in the exponential growth phase.
Animal Cancer Models
The current research adhered to the “Principles of Laboratory
Animal Care” of NIH and was carried out according to the
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protocols approved by the Institutional Animal Care and Use
Committee (IACUC). Nude mice were inoculated with hu-
man lung (A549) and ovarian (A2780) cancer cells or cells
isolated from malignant ascites obtained from patients with
ovarian carcinoma. All cancer cells were transfected with
luciferase. Orthotopic lung cancer mouse model was created
by intratracheal instillation of A549 lung cancer cells as pre-
viously described (15,42,43). Both orthotopic (intraperitoneal)
and xenograft (subcutaneous) ovarian cancer models were
created using A2780 or malignant ascites cells as previously
described (9,16). Luciferase transfected cancer cells were visu-
alized in live anesthetized animals using in-vivo biolumines-
cence IVIS system (Xenogen, Alameda, CA). Luciferin
(150 mg/kg) was intraperitoneally administered 10–15 min
before imaging. According to the IACUC policy, the size of
subcutaneous tumor was measured daily using a caliper and
the volume was calculated as d2×D/2 where d and D are the
shortest and longest diameters (in millimeters) of the tumor,
respectively. Once the tumor volume reached 200–300 mm3,
MMP2/LHRHMn3O4 nanoparticles were injected intraper-
itoneally in the volume of 0.1 μL into the mice. For melanoma
imaging studies, metabotropic glutamate receptor 1 (grm-1)
transgenic mouse model was developed as previously de-
scribed (13,44,45). The hallmark of the grm-1 transgenic mice
is the spontaneous development of pigmented cutaneous mel-
anomas. The melanoma development simulates that seen in
humans where cancer first develops on the ears, then eyelids
and then perianal region.
In vivo Optical and Magnetic Resonance Imaging
Mice were anesthetized with isoflurane (4% for induction of
anesthesia and 1–2% for maintenance) using XGI-8 Gas
Anesthesia System (Xenogen, Alameda, CA) for all imaging
procedures. MRI was performed using a 1 T M2™ whole
body scanner (Aspect Imaging, Shoham, Israel). Images (rep-
etition time 2,607 ms, echo time 44 ms) were recorded in Fast
Spin Echo sequence. At a spatial resolution of 312 μm, the
tumors were coronal imaged in a single section through the
mouse body using an image matrix of 256×256, a field of
view of 80 mm2, and 4 excitation. MR signal was calculated
using Vivoquant 1.21 software (Invicro, Boston, MA). For
MRI studies, mice were treated with 2 mg Mn2+ per kg body
mass administered intraperitoneally (2) either in a free form or
as the nanoparticle formulation.
Statistical Analysis
Data were analyzed using descriptive statistics and single-
factor ANOVA, and are presented as a mean ± SD from five
to ten independent measurements. Ten animals were used in
each experimental group. The power analysis (alpha=0.05;
power=80%) based on the preliminary results showed that
ten mice per group are needed for statistical analysis to deter-
mine a 15% difference between the groups. We analyzed data
sets for significance with Student’s t test and considered P
values of less than 0.05 as statistically significant.
RESULTS
Synthesis and Characterization of Water Soluble
Manganese Oxide Nanoparticles
Uniform hydrophobic Mn3O4 were synthesized at a low
temperature and normal atmospheric conditions. The reac-
tion yielded an average of approximately 150 mg of these
hydrophobic cores. The reaction time allowed for control of
crystal growth. Longer aging time led to synthesis of a larger
nanocrystal. The three hour aging time in this reaction yielded
cores with an average diameter of 6.17 nm. Previous investi-
gation assessed theX-ray diffraction pattern of the nanocrystal
synthesized using this procedure and identified the crystal as
having a tetragonal (hausmannite) structure (24).
These manganese oxide cores are very hydrophobic and
must be coated for clinical use. In addition to imparting water
solubility, the polymer coating protects the particles from
aggregation, limits hydrophobic interactions with cells
especially immune cells, helps to improve pharmacokinetics
and allows for further surface modification (46,47). Using a
dual solvent exchange method, the hydrophobic cores were
coated with lipid-PEG molecules to make them water soluble
and allow for further modification.
When the core was coated with DSPE-PEGmolecules, the
average size increased to 42.17±5.36 (mean ± SD) nm from
6.17±0.76 (mean ± SD) nm (P<0.05, Table I). The
PEGylated Mn3O4 NPs displayed narrow size distribution
and when stored at 4°C, they had excellent stability proper-
ties. At 164 days of storage, there were no significant changes
in mean particle size or particle size distribution (Fig. 1a).
The resulting NH2/MALMn3O4 NPs were then modified
first with a MMP2 cleavable peptide (Fig. 1b) and then with
luteinizing hormone-release hormone (LHRH) receptor
targeting peptide (Fig. 1c; please note a thioether linkage of
maleimide moiety on DSPE-PEG molecule with a cysteine
Table I Size of Manganese Oxide Nanoparticle. Means ± SD are shown
Particles Size,nm
Mn3O4 cores 6.17±0.76
NH2/MAL Mn3O4 NPs 42.17±5.36
MMP2/MAL Mn3O4 NPs 25.09±2.99
MMP2/LHRH Mn3O4 NPs 26.68±3.49
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residue on the LHRH peptide) to enable active targeting to
ovarian and lung cancers (12). Attachment of LHRH peptide
was confirmed using BCA protein assay (Thermo Fisher
Scientific Inc., Rockford, IL) according to manufacturer’s
protocol. The results of the BCA Assay indicated that in
average 1.52±0.33 (mean ± SD) mg LHRH peptide was
attached onto the surface of 10 mg of MMP2/LHRH
Mn3O4 NPs. The concentration of MMP2 cleavable peptide
was below the sensitivity level of the BCA Assay.
The MMP2/LHRH Mn3O4 NPs were digested with hy-
drochloric acid and purified to obtain a solution containing
manganese ions. A protocol used for determination of man-
ganese concentration in water and plants was modified for our
purpose. Based on our standard curve (MnCl2 solution in
deionized water), the Mn2+ concentration in the formulated
MMP2/LHRH Mn3O4 NPs was 48.28±7.59 (mean ± SD)
mg/L. This concentration was used for manganese content in
other experiments and was used for in vivo dosing (2 mg Mn2+
per kg mouse body weight).
Matrix metalloproteinases are extracellular enzymes
invo lved in a var i e ty o f func t ions inc lud ing
modification of the extracellular matrix. They are
present is almost all cell types and are seen in
increased quantity and activity in a variety of
pathologies including cancers including ovarian and
lung cancers and melanoma (48). Our results on two
different ovarian cancer cell lines show that MMP2 is
expressed nearly 5–6 folds higher in cells isolated from
malignant ascites (in vitro cell culture and ex vivo tumor
xenograft) obtained from patients with advanced ovarian
carcinoma when compared with A2780 ovarian cancer
cells (Fig. 2a).
The MMP2 peptide cleavage experiment showed that the
fluorescence signal from the peptide labelled with Cy5.5 near
infrared fluorescence dye decreased as the peptide was cleaved
and the cleaved fragment removed (Fig. 2b). The cleavage
between the glycine and isoleucine amino acids led to the
dissociation of Cy5.5-Gly-Pro-Leu-Gly fragment, which was
easily removed from the solution by centrifugal filtration. The
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Fig. 1 (a) Typical distribution of the size of PEGylated Mn3O4 nanoparticles
before and after the storage (164 days). (b) Chemical structures of MMP2
































































Fig. 2 (a) Expression of MMP2 mRNA. The expression was measured by
quantitative PCR in RNA isolated from: (1) A2780 human ovarian cancer cells;
(2) cells from malignant ascites obtained from patients with ovarian carcinoma
and grown in vitro; (3) tumor tissues from mice with xenografts of cancer cells
from malignant ascites obtained from patients with ovarian carcinoma. Means
± SD are shown. *P<0.05 when compared with A2780 human ovarian
cancer cells. (b) Cleavage of MMP2 peptide after incubation with human
MMP2 enzyme. Nanoparticles modified with cleavable MMP2 peptide were
incubated with 1 mg/mL of human MMP2 enzyme in HEPES buffered saline.
Representative fluorescence spectra are shown.
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Synthesis and Characterization of Vem-NLCs
The average particle size of Vem-NLCs was 174.51±31.76
(mean ± SD) nm. The entrapment of vemurafenib within the
NLCs was quantified based on the equations below. Based on
the HPLC calibration curve, our formulation was able
to entrap 6.23±1.09 (mean ± SD) mg of the 10 mg of
vemurafenib used in the synthesis yielding an entrap-










EE%-entrapment efficiency, DL%- drug loading, Wtotal-
weight of vemurafenib added during preparation, Wlipid-
weight of lipids used during preparation (Precirol ATO 5,
Isopropyl myristate, Soy PC), Wloaded- weight of vemurafenib
entrapped in Vem-NLC.
One of the primary advantages of entrapping chemother-
apeutics in nanoparticles is the reduction of free drug expo-
sure in the plasma and off-target organs and tissues. An ideal
nanocarrier would not release any drug in the blood circula-
tion. Accumulation in tumor tissue by active targeting or
enhanced permeation and retention (EPR) effect can allow
for degradation of the nanocarrier and release of entrapped
drug molecule. We examined by HPLC drug leakage and
retention in the NPs in PBS buffer (pH=7.4) within 72 h. The
HPLC measurements did not reveal a measurable amount of
vemurafenib in the dialysis buffer in these conditions. In
contrast, the amount of vemurafenib still entrapped in NLCs
did not change statistically significantly in the same conditions.
There was no change in retention time of vemurafenib as
detected by HPLC when assessing drug loading and particle
stability. Therefore, we concluded that the NLCs can retain
vemurafenib in plasma with normal pH for at least 72 h.
Cytotoxicity and Genotoxicity of Nanoparticle
Formulations
Cytotoxicity of MMP2/LHRH Mn3O4 NPs and NLCs were
assessed using CHO-K1 cells, which we used as a model for
normal healthy tissue. The results show that MMP2/LHRH
Mn3O4 NPs and empty NLCs are non-cytotoxic at concentra-
tions used in other experiments (Fig. 3a). In addition,
genotoxicity study demonstrated that empty MMP2/LHRH
Mn3O4 NPs are not likely to induce DNA damage (Fig. 4).
Negative (fresh medium) and positive (hydrogen peroxide) con-
trols were used as references. The assay also revealed that empty
NLCs do not cause appreciable DNA damage. Cytotoxicity of
free vemurafenib and encapsulated vemurafenib was assessed
using Colo829 melanoma cells, which contain the BRAF
V600E mutation. It was found that encapsulation of
vemurafenib within NLCs significantly increased its cytotoxicity
(Fig. 3b).
In vivo Animal Magnetic Resonance Imaging
The Mn3O4 NPs were tested as imaging agents in various
mouse models of cancer. The development of lung and intra-
peritoneal tumors in vivo was confirmed by the detection of
bioluminescence of cancer cells using IVIS imaging system in
anesthetized animals (Fig. 5a). The administration of
MMP2/LHRHMn3O4 NPs to the mice with orthotopic lung
cancer model substantially improved the visualization of the
cancermass in the lungs. Prior to contrast administration, only
a small mass is detected in the lower lobe of the right lung
(Fig. 5b). After injection of NPs, cancer cells were clearly
detected in the right lung (Fig. 5c). Consequently, the use of
NPs as contrast agents increased signal in the entire lung and
also brightened a potential metastatic mass on the periphery.
In the intraperitoneal model of ovarian cancer, the adminis-
tration of MMP2/LHRH Mn3O4 NPs not only increase













































Fig. 3 Cytotoxicity of nanoparticles (manganese oxide – Mn3O4 NPs and
nanostructured lipid carriers – NLCs). (a) Cellular viability of cells incubated
with nanoparticles that do not contain an anticancer drug. The cells were
incubated 24 h with nanoparticles indicated. The concentrations of nanopar-
ticles were 7.1 mg/L of Mn2+ and 80 mg/L of lipid for Mn3O4 and NLC,
respectively. (b) Cytotoxicity of free non-conjugated vemurafenib (Vem) and
NLC-encapsulated Vem. Colo 829 metastatic melanoma cells with the
targeted V600E mutation were incubated with free and encapsulated in
NLC-Vem. Means ± SD are shown. *P<0.05 when compared with free
vemurafenib.
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MMP2/ab733 Mn3O4 NPs were also used as the contrast
agents for the detection of melanoma in transgenic mice.
These mice spontaneously develop cutaneous melanoma le-
sions with frequent metastases. While the cutaneous lesions
are easily identifiable, better procedures are required for
detecting metastases. The use of NPs as contrast agents helped
to detect internal metastases in the right lung and in the
abdomen of the transgenic mice (Fig. 5c, lower panel).
In a subcutaneous ovarian cancer xenograft model, the
tumor mass is visible on the right flank of the mouse
(Fig. 6a). MMP2/LHRHMn3O4 NPs were injected subcuta-
neously on the contralateral side of the mouse. The time lapse
images show signal brightening at the site of the injection.
More impressively, the images clearly show the diffusion of the
tumor-targeted MMP2/LHRH Mn3O4 NPs from site of
administration to the tumor and preferential accumulation
in the primary tumor and metastases. Quantitative measure-
ments revealed that 45 min post-injection, the MR signal in
the tumor had increased by 22.3% (Fig. 6b).
DISCUSSION
In the present investigation, the manganese cores were syn-
thesized using manganese chloride, oleic acid, and oleylamine
as precursors. As the manganese chloride dissolved, it gave the
reaction solution a pinkish color. Later, this transitioned into
an orange to brown color. The addition of deionized water

























Figure 4 DNA damage potential
of nanoparticles. (a-d)
Representative fluorescence images
of cells with DNA damage after
treatment with (a) Negative control
(fresh medium); (b) Positive control
(hydrogen peroxide); (c) Mn3O4
NPs; (d) NLCs. (e) Quantitative
analysis of DNA damage evaluated
using a comet assay method. Means
± SD are shown. *P<0.05 when
compared with negative control.
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Mouse with Orthotopic Lung Cancer
Mouse with Orthotopic Ovarian Cancer
Tumor Tumor Tumor









Fig. 5 Enhancement in MRI
sensitivity and specificity by cancer-




magnetic resonance imaging. (b)
MRI without a contrast agent. (c)
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transition to a brown-black color indicates formation of nano-
particles (49). The reaction temperature plays a role in the
core shape; high reaction temperatures lead to one
dimensional rod formation whereas lower temperatures over
a longer time yield spherical nanocrystals. In this method for
crystallization, water acted as a reagent and the source for
oxygen, oleylamine acted as a base to catalyze the nucleation
of crystal, and the addition of oleic acid helped to create a
spherical nanocrystal as compared to nanocrystal plates (24).
The three hour aging time used for this study yielded particles
with an average diameter around 6 nm. Increasing the aging
time to 4 h resulted in the increase of average diameter of
cores to approximately 18 nm. The smaller cores were used
because of the potential for higher contrast resulting from the
higher surface area to volume ratio for the smaller core
compared to the larger core.
These hydrophobic cores cannot be used by themselves for
therapy and must be converted into a water-soluble, biocom-
patible form. Thin film hydration is a commonly used tech-
nique to coat hydrophobic nanoparticle cores with lipid-PEG
molecules to make water soluble nanoparticles. However, this
process results in irreversible aggregation of nanoparticles,
creation of empty micelles, and raises concerns of stability
issues. Using a dual solvent exchange method (50), in which
the hydrophobic cores are coated by changing the solvent
from chloroform to dimethyl sulfoxide to water results in a
higher surface coating density, more uniform distribution of
nanoparticles, and more stable nanoparticles. Because the
immiscibility of chloroform and water, an intermediary
solvent, dimethyl sulfoxide, was used in the present study to
transfer the core/lipid-PEG mixture into water as well as to
induce coating of the cores through hydrophobic interactions.
PEGylated Mn3O4 nanoparticles showed narrow size distri-
bution and no change in mean particle size or size distribution
after 164 days of storage (Fig. 1a).
The coating with lipid-PEG molecules endows free surface
functional groups, amines and maleimides, for further modi-
fication. MMP2 cleavable peptide was conjugated to the free
primary amines using a stable amide bond. LHRH cancer
targeting peptide was also attached via the cysteine to the
maleimide functional group forming a thioether bond. The
attachment of LHRH peptide was confirmed using the BCA
protein assay. The LHRH peptide developed a strong and
clear absorbance signal in this assay because of the presence of
aromatic structures on amino acid side chains in this peptide.
According to the manufacturer, the color formation of the
assay is principally due to the presence of certain amino acids
(cysteine, tryptophan, and tyrosine). These three amino acids
are present in the LHRH targeting peptide and are absent in
the MMP2 cleavable peptide. This difference in the compo-
sition of these peptides explains a strong color development in
the BCA assay for LHRH peptide and the absence of color
formation in case of the MMP2 cleavable peptide.
It was interesting that when the water soluble nanoparticles
were modified withMMP2 cleavable peptide, the average size
decreased from 42.17±5.36 (mean ± SD) nm to 25.09±2.99
(mean ± SD) nm. This phenomenon could probably be at-
tributed to a change in structure of the DSPE-PEGmolecules



























Tumor Tumor Tumor Tumor
Fig. 6 Distribution of cancer-
targeted Mn3O4 nanoparticles and
enhancement in MRI signal intensity.
(a) Representative MR images of a
mouse with subcutaneous
xenografts of human ovarian cancer
before (control) and 10, 30, and
45 min after injection of the cancer-
targeted nanoparticles. (b)
Quantitative analysis of MRI signal
intensity. Means ± SD are shown.
*P<0.05 when compared with
control.
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(51). The PEGmolecule on the surface of NH2/MALMn3O4
NPs likely maintains a “brush” configuration. The modifica-
tion of NPs with the MMP2 cleavable peptide, changes its
configuration to a “mushroom” configuration. Based on the
data obtained, this configuration appears to be maintained
after conjugation of LHRH targeting peptide. A nanoparticle
size between 10 and 100 nm is typically sought for most
intravenous applications. Nanoparticles larger than 200 nm
are subject to rapid elimination by the reticuloendothelial
system and those smaller than 10 nm can be efficiently
cleared by the kidney (52). This size range also allows for
passive tumor accumulation by the enhanced permeation
and retention effect. The increase in size of MMP2/LHRH
Mn3O4 NPs after coating with PEG showed that the used
synthetic conditions led to the covering of nanoparticles with a
substantial protective layer but did not result in a so-called
“thick” coating. A thinner core coating allows for an easier
passage of water to the core, liberation of Mn2+ ions, and
quicker core digestion; all three processes will be amicable in
increasing MR signal.
We hypothesized that the expression of MMP2 in the
tumor microenvironment can be considered as a hallmark
feature or cancers with high metastatic potential and, conse-
quently, MMP2 cleavable peptide can be used to enhance the
detection of metastases by MRI. In order to verify this hy-
pothesis, we measured the MMP2 expression in established
ovarian cancer cells and highly metastatic cancer cells isolated
from malignant ascites obtained from patients with advanced
ovarian carcinoma using quantitative PCR. The results of
these measurements showed that highly metastatic cancer cells
had a 5–6 - fold higher expression of MMP2 mRNA when
compared with A2780 ovarian cancer cells. It is possible that
the digestion of the peptide is correlated to the expression and
activity of MMP2 enzyme. Consequently, the increase release
of the biotin-fragment from the avidin-modified MMP2 pep-
tide used in the present study after its cleavage in the tumor
could potentially represent an attractive target for avidin-
conjugated nanoparticles containing a therapeutic agent. We
are planning to use such avidin-modified nanoparticles for
targeted chemotherapy after the pretreatment with biotin
modified MMP2 cleavable peptide on the surface of the
Mn3O4 NPs. Once the biotin-Gly-Pro-Leu-Gly fragment is
dissociated, it can act as a signal to recruit avidin-modified
therapeutic drug containing nanoparticles to the tumor sites.
This will provide a basis for the responsive theragnostic plat-
form in which the therapeutic payload is preferentially deliv-
ered to tumors with high activity of MMP2 enzymes (i.e.
containing highly metastatic cancer cells).
In the current study, two substantially different lipids were
used for synthesis of NLC. Precirol® ATO 5 consists of
glycerol distearate (type I) EP, glyceryl distearate NF, and
glyceryl palmitostearate (USA FDA IIG). The combination
of spatially different lipids results in an imperfect solid matrix.
The addition of a specialized liquid lipid such as isopropyl
myristate prevents the crystallization of the matrix to β forms
caused an amorphous matrix (53). The combination of the
two processes may yield a NLC with high drug loading and
reduced drug expulsion. This appears to be evident from our
results. Tween 80 and DSPE-PEG-NH2 were added to im-
prove water solubility of the lipid carrier. The primary amine
on the DSPE-PEG-NH2 can be used to add other function-
alities in the future such as targeting ligands such as avidin. A
study by Bocca et al. (54) showed that PEGylated or stealth
solid lipid nanoparticles had reduced phagocytosis rate com-
pared to non-stealth counterparts. The increased circulation
time will increase the likelihood of the nanoparticles to be
recruited to tumor sites.
There is a restriction on the use of gadolinium chelateMRI
contrast agents because of the potential of nephrogenic sys-
temic fibrosis . Several iron based contrast agents have been
withdrawn from market due to safety concerns or
discontinued by the manufacturer. GastroMARK® is the
only available iron oxide contrast agent available and is
approved for imaging of the gastrointestinal tract (55,56).
However, performing solely a cytotoxicity assay does not
adequately address safety concerns. Previously, we showed
that even at safe levels, nanoparticles may impose negative
effects on healthy tissues, e.g. induce genetic aberrations (57).
The CometAssay® allows for the visualization of DNA dam-
age caused by treatment with nanoparticles. After cells are
treated with the nanoparticles, any DNA damage resulting in
fragmentation appears as tails after electrophoresis. Long tails
and more intense SYBR Gold® staining in the tail are indi-
cations of DNA damaging potential of nanoparticles. The
results of this assay indicated that MMP2/LHRH Mn3O4
NPs and empty NLCs did not demonstrate signs of DNA
damage and thus are safe for in vivo use.
Free anticancer drugs have large volumes of distribution
and therefore may have adverse side effects on normal tissues,
fast clearance, and reach insufficient concentrations at tumor
sites. Delivery of anticancer drugs using nanoparticles has the
realistic potential of overcoming these deficiencies. Lipid-
based nanoparticles are composed of biocompatible materials
and are ideal in incorporating lipohilic compounds. Unlike
solid lipid nanoparticles, the inclusion of a liquid lipid in our
formulation results in nanostructured lipid carriers. The liquid
lipid (isopropyl myristate) fills the gaps in the crystal structure
of the solid lipid (Precirol ATO 5). The drug molecule is
solubilized in the liquid lipid portion of the formulation for
NLCs as opposed residing in the gaps of the crystal structure
of SLNs. Although NLCs have been shown to have higher
entrapment of small drug molecules and less significant drug
leakage, the liquid lipid portion appears to be the limiting
factor for drug loading as the amount of drug entrapped is
partially determined by its solubility in the liquid lipid. The
current formulation was able to achieve 62.3% entrapment
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efficiency. Increasing the amount of drug in the pre-synthesis
reaction did not increase loading. Therefore, the limiting factor
may be the solubility of vemurafenib in isopropyl myristate.
The encapsulation of an anticancer agent within the matrix
of a nanocarrier ensures that healthy tissues are not exposed to
the substance. There was no release of vemurafenib from the
liquid lipid filled matrix of the NLCs in neutral pH in PBS
buffer for at least 72 h. Therefore, release of free drug would
require nanoparticle digestion, which can occur in the lyso-
somal environment of cancer cells.
The cytotoxicity potential of the NLC entrapped
vemurafenib formulation was assessed in Colo 829 human met-
astatic melanoma cell line. This cell line has the BRAF V600E,
which is found in a large proportion ofmelanomas. Vemurafenib
was developed as a molecularly targeted agent for this mutation.
Because of its specificity to the mutation, vemurafenib should be
effective in melanoma cells and not induce severe adverse side
effects on normal cells. However, clinical use of the drug has
shown the potential for the development of squamous cell carci-
nomas (58). Delivery within a NLC can increase accumulation in
melanoma cells and spare healthy skin tissue.
MTT cytotoxicity assay in Colo 829 revealed that encap-
sulation of the drug into nanocarriers significantly increased its
cytotoxicity when compared with free non-encapsulated
vemurafenib. The comparison of these finding with other
results of the present study shows the potential of the cancer-
targeted Vem-NLCs formulations for decreasing systemic ex-
posure to vemurafenib and increasing its cytotoxicity specifi-
cally in malignant melanoma cells.
Administration of MMP2/LHRHMn3O4 NPs into a sub-
cutaneous ovarian cancer model resulted in a significant in-
crease in MR signal intensity. After 45 min, the signal had
improved in average by 22.3%. The entire tumor mass
showed an increase in signal demonstrating that the nanopar-
ticles had preferentially accumulated in the tumors. This is
important in the diagnosis of cancer because the more accu-
rate determination of the size of the tumor can help in deter-
mining the next steps in therapy. High sensitivity of MRI
combined the proposed imaging contrast NPs will help in
early cancer diagnostics and detection of metastases. Also,
imaging procedures can be used for monitoring therapy prog-
nosis and decrease in tumor size. The preferential accumula-
tion of cancer-targeted NPs in tumors was confirmed by
monitoring the passage of the NPs from the administration
site to the tumor xenograft with time. In addition to the
subcutaneous model, Mn3O4 NPs were evaluated in
orthotopic mouse models that resemble a similarity to cancer
development in humans. The pre- and post-dose images
demonstrate the power of the Mn3O4 NPs as MR imaging
agents and showed a significant increase in the MR signal
(Table II). Also, this experiment demonstrates that the parti-
cles are not simply deposited, but selectively accumulate in
tumor tissue. In fact, the lungs without tumors demonstrated
no signal even after injection of the contrast agent.
Although the intraperitoneal ovarian primary tumor with
malignant ascites has some signal intensity without contrast
administration, the post-dose image not only shows an in-
crease in the signal but also demonstrated the delineation of
the tumor shapes. Changing the targeting ligand from LHRH
peptide to ab733 anti-melanoma monoclonal antibodies al-
lows the particles to be adapted for use for detection of
melanoma. The PEGylated Mn3O4 NPs provide an excellent
foundation for further modification to meet required needs.
The MMP2/ab733 Mn3O4 NPs showed increased signal in
two sites of melanoma metastasis.
MRI revealed that the signal began to decrease 30 min
after injection of NPs. The circulation time appears to be
ample for tumor accumulation and short enough to prevent
deposition in healthy tissues, which can limit potential adverse
side effects. The circulation time is likely to be dependent on
the size of the nanoparticles, but further studies will need to be
conducted for the confirmation of such conclusion.
Compared to other studies using that also used manganese
oxide based imaging agents for in vivo studies (2,3,22), the dose
(Mn2+ concentration) in the current study was chosen to be at
the substantially lower range. It is important to use the lowest
effective dose to prevent toxicity especially for nanoparticles
that will be administered repeatedly. The proposed Mn3O4
NPs have the potential to be effectively used for diagnosis of
various cancers andmonitoring therapy prognosis. The ability
of the particles to clearly outline shape of tumor masses can be
used to monitor decrease in tumor volume.
CONCLUSION
An original design of cancer targeted responsive nanoparticle-
based systems for magnetic resonance imaging and treatment
of different cancers was proposed. Two types of nanoparticles
were developed based on PEGylated water soluble Mn3O4
Table II Increase in Magnetic Resonance Signal Intensity Post-Dose
Post-Dose 15 min 30 min
Lung Cancer No difference +15% No difference
Ovarian Primary Tumor and Malignant Ascites Slight brightening Delineation of tumor masses Delineation of tumor masses
Primary and Metastatic Melanoma +59.26% +69.51% +17.64%
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nanoparticles and nanostructured lipid carriers. The nano-
particles were modified with cancer-targeting moiety (LHRH
peptide or anti-melanoma antibodies). The possibility of mod-
ification with other peptides (e.g. biotinylatedMMP2 cleavable
peptide) and encapsulation of anticancer drugs (e.g.
vemurafenib) was also verified and tested. Synthesized nano-
particles were evaluated in vitro and in vivo using different
models of cancer (transgenic mice developedmelanoma, nude
mice with orthotopic human lung and ovarian cancers, as well
as subcutaneous xenografts of ovarian cancer). The results of
the present investigation showed substantial advantages of the
proposed nanoparticles as MRI contrasting agents. The usage
of these nanoparticles significantly amplified a magnetic reso-
nance signal specifically from cancer cells and improved the
detection of primary tumors, precise determination of their
shape, and visualization of metastases. Preferential accumula-
tion of cancer targeted nanoparticles in cancer cells not only
enhanced the sensitivity of MRI but also open a door for
targeted treatment of various types of cancer.
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